<DOC>
	<DOCNO>NCT01376232</DOCNO>
	<brief_summary>Study Assess Pharmacokinetics GSK1278863A Coadministered High Fat Meal Inhibitor CYP2C8 ( gemfibrozil ) , ]</brief_summary>
	<brief_title>Study Assess Pharmacokinetics GSK1278863A Coadministered With High Fat Meal Inhibitor CYP2C8 ( Gemfibrozil )</brief_title>
	<detailed_description>The purpose study assess clinical drug-drug interaction potential GSK1278863A medication inhibitor CYP2C8 enzyme order support co-administration similar agent later phase development . Specifically . study ass pharmacokinetics single dose GSK1278863A administer alone co-administered gemfibrozil , potent inhibitor CYP2C8 , follow steady-state oral administration gemfibrozil . Finally , support co-administration GSK1278863A food , study ass pharmacokinetics single oral dose GSK1278863A fast condition follow standard high-calorie , high fat meal .</detailed_description>
	<mesh_term>Gemfibrozil</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure Male female 18 55 year age inclusive , time signing inform consent A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 5 terminal halflives postlast dose Body weight &lt; 50 kg BMI within range 19 29.9 kg/m2 ( inclusive ) Capable give write informed consent , include compliance requirement restriction list consent form QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) The value hematological parameter screen : Any value outside reference range A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepines The value follow test screen : Serum ferritin : outside reference range A positive test HIV antibody Clinically significant CPK &gt; 3 X ULN deem clinically significant investigator Calculated creatinine clearance : &lt; 80 mL/min Subjects preexisisting condition interfere normal gastrointestinal anatomy motility , and/or hepatic functionthat could interfere absorption , metabolism , and/or excretion study drug . Examples condition could interfere normal gastriointestinal anatomy motility include cholecystectomy , vagotomy , malabsorption , Crohn 's disease , ulcerative colitis , celiac sprue History regular alcohol consumption within 6 month study define : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 12 week , 5 halflives twice duration biological effect investigational product ( whichever longer ) History peptic ulcer disease History malignancy tumor . Nonmelanoma skin cancer definitely remove allow Exposure four new chemical entity within 12 month prior first dose day Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation Where participation study would result donation blood blood product excess 500 mL within 56 day period Pregnant female determine positive serum urine hCG test screen prior dose Lactating female Unwillingness inability follow procedure outline protocol Subject mentally legally incapacitated History sensitivity heparin heparininduced thrombocytopenia Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen Consumption red wine , apple , star fruit , citrus fruits/juices include blood orange ( exception orange , mandarin lemon ) 7 day prior first dose study medication , unless opinion Investigator GSK Medical Monitor interfere study procedure compromise subject safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Anaemia</keyword>
	<keyword>Drug- Drug Interaction</keyword>
</DOC>